These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 21107923)

  • 1. Diseases affecting bone quality: beyond osteoporosis.
    Unnanuntana A; Rebolledo BJ; Khair MM; DiCarlo EF; Lane JM
    Clin Orthop Relat Res; 2011 Aug; 469(8):2194-206. PubMed ID: 21107923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors affecting bone strength other than osteoporosis.
    Ratti C; Vulcano E; Canton G; Marano M; Murena L; Cherubino P
    Aging Clin Exp Res; 2013 Oct; 25 Suppl 1():S9-11. PubMed ID: 24046057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The actions of parathyroid hormone on bone: relation to bone remodeling and turnover, calcium homeostasis, and metabolic bone disease. Part IV of IV parts: The state of the bones in uremic hyperaparathyroidism--the mechanisms of skeletal resistance to PTH in renal failure and pseudohypoparathyroidism and the role of PTH in osteoporosis, osteopetrosis, and osteofluorosis.
    Parfitt AM
    Metabolism; 1976 Oct; 25(10):1157-88. PubMed ID: 787723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insights into material and structural basis of bone fragility from diseases associated with fractures: how determinants of the biomechanical properties of bone are compromised by disease.
    Chavassieux P; Seeman E; Delmas PD
    Endocr Rev; 2007 Apr; 28(2):151-64. PubMed ID: 17200084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone quality and osteoporosis therapy.
    Martin RM; Correa PH
    Arq Bras Endocrinol Metabol; 2010 Mar; 54(2):186-99. PubMed ID: 20485908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Important determinants of bone strength: beyond bone mineral density.
    Friedman AW
    J Clin Rheumatol; 2006 Apr; 12(2):70-7. PubMed ID: 16601540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fragility fractures in men with idiopathic osteoporosis are associated with undermineralization of the bone matrix without evidence of increased bone turnover.
    Fratzl-Zelman N; Roschger P; Misof BM; Nawrot-Wawrzyniak K; Pötter-Lang S; Muschitz C; Resch H; Klaushofer K; Zwettler E
    Calcif Tissue Int; 2011 May; 88(5):378-87. PubMed ID: 21318401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomechanics of bone: determinants of skeletal fragility and bone quality.
    Turner CH
    Osteoporos Int; 2002; 13(2):97-104. PubMed ID: 11905527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The therapeutic effects of alfacalcidol on bone strength, muscle metabolism and prevention of falls and fractures.
    Schacht E; Richy F; Reginster JY
    J Musculoskelet Neuronal Interact; 2005; 5(3):273-84. PubMed ID: 16172518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The bone quality framework: determinants of bone strength and their interrelationships, and implications for osteoporosis management.
    Felsenberg D; Boonen S
    Clin Ther; 2005 Jan; 27(1):1-11. PubMed ID: 15763602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of vitamin D on bone and osteoporosis.
    Lips P; van Schoor NM
    Best Pract Res Clin Endocrinol Metab; 2011 Aug; 25(4):585-91. PubMed ID: 21872800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced bone mineral density in male renal transplant recipients: evidence for persisting hyperparathyroidism.
    Roe SD; Porter CJ; Godber IM; Hosking DJ; Cassidy MJ
    Osteoporos Int; 2005 Feb; 16(2):142-8. PubMed ID: 15258722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [New methods for the evaluation of bone quality. Diseases Affecting Bone Quality.].
    Yamada S; Inaba M
    Clin Calcium; 2017; 27(8):1097-1103. PubMed ID: 28743845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protecting Bone Health in Pediatric Rheumatic Diseases: Pharmacological Considerations.
    Zhang Y; Milojevic D
    Paediatr Drugs; 2017 Jun; 19(3):193-211. PubMed ID: 28290112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of osteoporosis in rheumatoid arthritis patients.
    Hoes JN; Bultink IE; Lems WF
    Expert Opin Pharmacother; 2015 Mar; 16(4):559-71. PubMed ID: 25626121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone quality: the determinants of bone strength and fragility.
    Fonseca H; Moreira-Gonçalves D; Coriolano HJ; Duarte JA
    Sports Med; 2014 Jan; 44(1):37-53. PubMed ID: 24092631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The importance of growth hormone (GH) and GH secretagogues for bone mass and density.
    Svensson J
    Curr Pharm Des; 2002; 8(23):2023-32. PubMed ID: 12171516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of biochemical markers of bone turnover and bone mineral density in management of osteoporosis.
    Vasikaran SD
    Crit Rev Clin Lab Sci; 2008; 45(2):221-58. PubMed ID: 18415816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of osteoporosis medications on bone quality.
    Benhamou CL
    Joint Bone Spine; 2007 Jan; 74(1):39-47. PubMed ID: 17196423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of collagen in bone strength.
    Viguet-Carrin S; Garnero P; Delmas PD
    Osteoporos Int; 2006; 17(3):319-36. PubMed ID: 16341622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.